Navigation Links
Double-therapy approach effectively inhibited brain cancer recurrence
Date:8/24/2010

PHILADELPHIA Researchers from the University of Massachusetts Medical School have identified a novel approach of combining chemotherapy with a targeted therapy to decrease the recurrence of glioblastoma multiforme, the most common and aggressive brain tumor.

"Glioblastomas are horrendous tumors, and new therapies are desperately needed," said lead researcher Alonzo H. Ross, Ph.D., professor of biochemistry and molecular pharmacology at the University of Massachusetts Medical School.

"We found that this double therapy of combining temozolomide with a Notch inhibitor was highly effective at treating tumor cells in culture and in mice," he added.

Results of this study are published in the September issue of Cancer Research, a journal of the American Association for Cancer Research.

Despite treatment with surgery, radiotherapy and chemotherapy, glioblastoma prognosis and survival rates are poor. This may in part be due to the fact that some cells within the tumor cancer stem cells are more resistant to these therapies, eventually allowing the tumor to recur, according to Ross.

"We're both very successful and unsuccessful with cancer therapy; in most cases we can substantially diminish the tumor mass. The problem is that it comes back with vengeance, and is even more resistant and difficult to treat," he said.

Temozolomide is one chemotherapeutic agent that helps patients with glioblastomas live longer; two-year survival rates increase from approximately 10 percent with radiation alone to 25 percent when temozolomide is combined with radiation, according to Ross. Likewise, data have indicated that the Notch signaling pathway is often over-expressed in glioma tissue and tumor cells.

Ross and colleagues evaluated this double-therapy approach of combining temozolomide with a Notch inhibitor in cell culture and in immunodeficient mice to determine if this combination therapy enhances therapy
'/>"/>

Contact: Tara Yates
tara.yates@aacr.org
267-646-0558
American Association for Cancer Research
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Survival benefit with high-intensity end-of-life approaches
2. Mountain Home 'Doing the Right Thing Really is the Best Business Approach'
3. ICU Patients Gain From Team Approach to Care
4. Short on specialized intensive care physicians, team-based approach improves ICU outcomes
5. Lumension Unveils Intelligent Application Whitelisting that Operationalizes a Proactive Endpoint Security Approach
6. Secretary Clintons Approach to Development: Good Rhetoric, Little Action?
7. New Approaches to Teen Therapy Bring Results
8. New Drugs, Approaches Offer Hope Against Prostate Cancer
9. New approach to immune cell analysis seen as first step to better distinguish health and disease
10. Reovirus may be a novel approach to prostate cancer treatment
11. Effort aims to spike breast cancer with new approach
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Double-therapy approach effectively inhibited brain cancer recurrence
(Date:5/4/2015)... Atlanta, Georgia (PRWEB) May 04, 2015 Each ... the country to raise funds and awareness for breast cancer. ... Plastic Surgery will be featured as the entertainment sponsor for ... the Cure” on May 9 at the Lenox Square Mall. ... year’s Atlanta race, and to raise $1.2 million. Perimeter Plastic ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be ... Group (RUG) Conference in Baltimore, MD from May 11 ... Group provides an opportunity for clients to gather to ... , In addition to sponsoring the event, TROY Healthcare ... RUG Conference. Attendees can stop by the TROY booth ...
(Date:5/4/2015)... May 04, 2015 In May of 2010, ... his own life. In the wake of this tragedy, Ty’s ... an organization that exposes the grim reality of bullying and ... platform for Kirk and Laura to share their story and ... from happening to another family — a mission that took ...
(Date:5/4/2015)... 04, 2015 EY today announced that ... a finalist for the EY Entrepreneur Of The Year® ... awards program recognizes entrepreneurs who demonstrate excellence and extraordinary ... personal commitment to their businesses and communities. Mr. ... of independent judges. Award winners will be announced ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 New findings ... Brain Tumor Association (ABTA) show that people diagnosed with ... and treatment options, including clinical trials, at the time ... to make difficult decisions about their course of treatment. ... of the first nationwide brain tumor volunteer network, the ...
Breaking Medicine News(10 mins):Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
... center, which can go awry , , WEDNESDAY, Jan. 23 ... part of the brain handles what might be called ... lead scientists closer to more effective treatments for a ... brain region is helpful because it provides insight into ...
... fingertips to tap or press a surface is essential ... use a BlackBerry or an iPhone. But researchers ... seemingly trivial action is the result of a complex ... nervous system and muscles of the hand. , ...
... 23, 2008RNA interference (RNAi) represents an innovative new strategy ... associated with disease processes, and a series of review ... RNAi and microRNAs will begin with two review papers ... of Human Gene Therapy, a peer-reviewed journal published by ...
... increased by 18.0% to ... - Medical enrollment grew by 708,000 members during 2007, - Selling, general and ... by 120 basis points during the year, - Operating cash flow exceeded $4.3 billion for the year, or 1.3 ... income, - Company reiterates ...
... KIRKLAND, Wash., Jan. 23 "A failing mind, not ... today," says Cameron,Truesdell, CEO of LTC Financial Partners, the ... be, so we,re going to give,our clients information to ... offering a free guidebook and web links to helpful ...
... for Gestiva(TM) Anticipated in Calendar 2008, Gestiva(TM), is Designated ... Prevention ... in Singleton Pregnancies, ST. LOUIS, Jan. 22 ... company that,develops, manufactures, acquires and markets technology-differentiated,branded and generic/non-branded ...
Cached Medicine News:Health News:Specific Brain Region Governs Problem-Solving Skills 2Health News:Specific Brain Region Governs Problem-Solving Skills 3Health News:What gives us fingertip dexterity? 2Health News:What gives us fingertip dexterity? 3Health News:The RNA drug revolution -- a new approach to gene therapy 2Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 2Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 3Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 4Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 5Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 6Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 7Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 8Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 9Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 10Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 11Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 12Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 13Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 14Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 15Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 16Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 17Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 18Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 19Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 20Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 21Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 22Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 23Health News:Long Term Care Insurance Leader Offers Advice on Preventing Dementia, the Leading Cause of Care Claims 2Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 2Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 3Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 4Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 5
(Date:5/4/2015)... Calif. , May 4, 2015 Rogne ... for psoriasis, today announced that preclinical and mechanism of ... at the Society of Investigative Dermatology (SID) Annual Meeting ... in Atlanta, Georgia . ... advancing the development of RON2315, a novel, low MW ...
(Date:5/4/2015)... WHIPPANY, N.J. , May 4, 2015 ... agreement with Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... clinical development for the prevention of thrombosis. Under the ... in areas of high unmet medical need. As ... evaluate the therapeutic profile of ISIS-FXI Rx in ...
(Date:5/4/2015)... BUFFALO, N.Y. , May 4, 2015 /PRNewswire/ ... Stephanie Englert , PharmD, has completed preliminary analysis ... Disorder and Schizophrenia. Resources from Clinical Support Services, ... Medication Reviews (CMR) with patients currently taking psychiatric ... events. The research found that 93% of patients ...
Breaking Medicine Technology:Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3
... 2, 2012 New Report Added in ... (General, Local, Adjunctive) The World Anesthesia ... , General Anesthesia Local Anesthesia ...   To Browse Full TOC, Tables & Figures visit: ...
... SAN DIEGO, May 2, 2012 Zogenix, Inc. (NASDAQ: ... developing products for the treatment of central nervous system ... submitted a New Drug Application (NDA) to the U.S. ... extended-release capsules), Zogenix,s lead investigational product candidate for the ...
Cached Medicine Technology:ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 2ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 3ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 4ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 5ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 6Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 2Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 3Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 4Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 5Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 6
... a user friendly computerized medical record system ... and productivity of the practice as well ... documentation. It provides clinical templates for commonly ... It also contains an exhaustive database to ...
... There is an important movement in our ... for handicapped persons. In fact, recent government ... both. This ingenious device affords your wheelchair-bound ... lane of equipment without having to leave ...
... ReSeeVit CR-DGi Retinal Camera System is an ... retinal segment images for documentation, diagnosis and ... CR-DGi retinal camera for optimal performance. We ... designed for anterior segment images. ReSeeVit is ...
... system combines continuous access, random ... a broad testing menu. AxSYM ... clinical laboratories to process a ... as well as adding tests ...
Medicine Products: